News stories about Affimed (NASDAQ:AFMD) have trended somewhat positive on Sunday, Accern Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Affimed earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 47.0502393378178 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- BMO Capital Markets Trims Affimed (AFMD) Target Price to $4.00 (americanbankingnews.com)
- Affimed Therapeutics (AFMD) CEO Adi Hoess on Q2 2018 Results – Earnings Call Transcript (seekingalpha.com)
- Affirmed Therapeutics (AFMD) Reports Q2 Loss, Misses Revenue Estimates (finance.yahoo.com)
- Affimed (AFMD) Set to Announce Earnings on Wednesday (americanbankingnews.com)
Shares of Affimed remained flat at $$1.60 during midday trading on Friday, according to MarketBeat Ratings. The stock had a trading volume of 534,695 shares, compared to its average volume of 185,715. Affimed has a 1 year low of $1.15 and a 1 year high of $2.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.36 and a quick ratio of 5.57. The stock has a market cap of $99.82 million, a PE ratio of -2.05 and a beta of 2.35.
Affimed (NASDAQ:AFMD) last issued its earnings results on Tuesday, May 15th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, meeting the consensus estimate of ($0.18). The company had revenue of $0.65 million during the quarter, compared to analysts’ expectations of $0.54 million. Affimed had a negative return on equity of 74.04% and a negative net margin of 1,723.04%. research analysts expect that Affimed will post -0.69 EPS for the current fiscal year.
A number of equities analysts have recently issued reports on AFMD shares. Zacks Investment Research cut Affimed from a “hold” rating to a “sell” rating in a report on Tuesday, May 22nd. ValuEngine upgraded Affimed from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd. Finally, BMO Capital Markets cut their price objective on Affimed from $6.00 to $4.00 and set an “outperform” rating for the company in a report on Thursday.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Recommended Story: What does earnings per share mean?
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.